Table 1.

In vitro activity of TD-1792 against S. aureus isolates

S. aureus (no. tested) and antibiotic	MIC (μg/ml)			% Susceptiblea
	Range	50%	90%
Methicillin susceptible (164)
TD-1792	0.002–0.03	0.008	0.015	NA
Oxacillin	≤0.06–2	0.25	0.5	100
Vancomycin	≤0.25–2	1	1	100
Daptomycin	0.06–1	0.5	0.5	100
Linezolid	1–4	2	4	100
Clindamycin	≤0.5–>4	≤0.5	≤0.5	93.3
Ciprofloxacin	0.12–>8	0.5	2	89.0
Gentamicin	≤0.06–>16	0.5	2	97.0
Erythromycin	≤0.12–>16	1	>16	23.2
Trimethoprim-sulfamethoxazole	≤0.5/9.5–2/38	≤0.5/9.5	≤0.5/9.5	100
Methicillin resistant (324)
TD-1792	0.008–0.03	0.015	0.03	NA
Vancomycin	≤0.25–2	1	1	100
Daptomycin	0.12–2	0.5	0.5	99.7
Linezolid	1–4	2	4	100
Clindamycin	≤0.5–>4	≤0.5	>4	66.4
Ciprofloxacin	0.12–>8	8	>8	26.2
Gentamicin	≤0.06–>16	1	>16	73.5
Erythromycin	0.5–>16	>16	>16	1.5
Trimethoprim-sulfamethoxazole	≤0.5/9.5–>4/76	≤0.5/9.5	≤0.5/9.5	90.7
Heterogeneous vancomycin intermediate (39)
TD-1792	0.015–0.06	0.03	0.03	NA
Vancomycin	0.5–2	1	2	100
Daptomycin	0.25–2	0.5	1	97.4
Linezolid	1–2	2	2	100
Clindamycin	≤0.5–>4	>4	>4	5.1
Ciprofloxacin	2–>8	>8	>8	0
Gentamicin	0.5–>16	>16	>16	20.5
Erythromycin	>16	>16	>16	0
Trimethoprim-sulfamethoxazole	≤0.5/9.5–>4/76	>4/76	>4/76	48.7

^aSusceptibility of each agent as defined by CLSI document M100-S21 (4).